TN2013000394A1 - Derives de pyrrolo [2,3-d] pyrimidine servant d'inhibiteurs de kinases apparentees a la tropomyosine - Google Patents

Derives de pyrrolo [2,3-d] pyrimidine servant d'inhibiteurs de kinases apparentees a la tropomyosine

Info

Publication number
TN2013000394A1
TN2013000394A1 TNP2013000394A TN2013000394A TN2013000394A1 TN 2013000394 A1 TN2013000394 A1 TN 2013000394A1 TN P2013000394 A TNP2013000394 A TN P2013000394A TN 2013000394 A TN2013000394 A TN 2013000394A TN 2013000394 A1 TN2013000394 A1 TN 2013000394A1
Authority
TN
Tunisia
Prior art keywords
tropomyosin
pyrrolo
inhibitors
pyrimidine derivatives
related kinases
Prior art date
Application number
TNP2013000394A
Other languages
English (en)
Inventor
Mark David Andrews
Sharanjeet Kaur Bagal
Karl Richard Gibson
Kiyoyuki Omoto
Thomas Ryckmans
Sarah Elizabeth Skerratt
Paul Anthony Stupple
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45937493&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2013000394(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of TN2013000394A1 publication Critical patent/TN2013000394A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne des composés de formule (I) et leurs sels pharmaceutiquement acceptables, dans lesquels les substituants répondent aux descriptions figurant dans le présent mémoire, et leur utilisation en médicine, en particulier comme antagonistes de TrK.
TNP2013000394A 2011-04-05 2013-09-27 Derives de pyrrolo [2,3-d] pyrimidine servant d'inhibiteurs de kinases apparentees a la tropomyosine TN2013000394A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161471758P 2011-04-05 2011-04-05
PCT/IB2012/051363 WO2012137089A1 (fr) 2011-04-05 2012-03-22 Dérivés de pyrrolo-[2,3-d]pyrimidine en tant qu'inhibiteurs des kinases associées à la tropomyosine

Publications (1)

Publication Number Publication Date
TN2013000394A1 true TN2013000394A1 (fr) 2015-01-20

Family

ID=45937493

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2013000394A TN2013000394A1 (fr) 2011-04-05 2013-09-27 Derives de pyrrolo [2,3-d] pyrimidine servant d'inhibiteurs de kinases apparentees a la tropomyosine

Country Status (31)

Country Link
US (2) US8846698B2 (fr)
EP (1) EP2694509B1 (fr)
JP (1) JP5595616B2 (fr)
KR (1) KR20130133905A (fr)
CN (1) CN103534257A (fr)
AP (1) AP2013007159A0 (fr)
AR (1) AR085852A1 (fr)
AU (1) AU2012238369A1 (fr)
BR (1) BR112013025792A2 (fr)
CA (1) CA2832291C (fr)
CL (1) CL2013002821A1 (fr)
CO (1) CO6801740A2 (fr)
CR (1) CR20130470A (fr)
CU (1) CU20130129A7 (fr)
DO (1) DOP2013000221A (fr)
EA (1) EA201391239A1 (fr)
EC (1) ECSP13013009A (fr)
ES (1) ES2581848T3 (fr)
GE (1) GEP20156417B (fr)
GT (1) GT201300236A (fr)
IL (1) IL228590A0 (fr)
MA (1) MA35024B1 (fr)
MX (1) MX2013011612A (fr)
NI (1) NI201300103A (fr)
PE (1) PE20141050A1 (fr)
SG (1) SG193513A1 (fr)
TN (1) TN2013000394A1 (fr)
TW (1) TWI443101B (fr)
UA (1) UA108926C2 (fr)
UY (1) UY34004A (fr)
WO (1) WO2012137089A1 (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201350481A (zh) * 2012-05-11 2013-12-16 Abbvie Inc Ｎａｍｐｔ抑制劑
WO2014053968A1 (fr) 2012-10-04 2014-04-10 Pfizer Limited Inhibiteurs de kinase associée à la tropomyosine pyrrolo[3,2-c]pyridine
JP2015531394A (ja) 2012-10-04 2015-11-02 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ ピロロ［２，３−ｄ］ピリミジントロポミオシン関連キナーゼ阻害剤
JP2015531393A (ja) * 2012-10-04 2015-11-02 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ トロポミオシン関連キナーゼ阻害剤
WO2014110574A1 (fr) 2013-01-14 2014-07-17 Incyte Corporation Composés de carboxamide aromatique bicyclique utiles comme inhibiteurs de pim kinase
ME03780B (fr) 2013-01-15 2021-04-20 Incyte Holdings Corp Dérivés de thiazolecarboxamide et pyridinecarboxamide et leur utilisation comme inhibiteurs des kinases pim
TWI630194B (zh) 2013-03-14 2018-07-21 凱立拉製藥公司 雙環止痛化合物
JP2016169161A (ja) * 2013-07-19 2016-09-23 大日本住友製薬株式会社 新規イミダゾピリジン化合物
CN105658653A (zh) 2013-08-23 2016-06-08 因赛特公司 可用作pim激酶抑制剂的呋喃并-和噻吩并-吡啶甲酰胺化合物
US9067914B1 (en) 2013-12-10 2015-06-30 Genzyme Corporation Tropomyosin-related kinase (TRK) inhibitors
JP6542794B2 (ja) 2013-12-12 2019-07-10 ゼノ ロイアルティー アンド マイルストーンズ リミテッド ライアビリティー カンパニー 二環式アルキル化合物、および合成
CA2934010A1 (fr) 2013-12-20 2015-06-25 Pfizer Limited Inhibiteurs de kinase apparentes a la n-acylpiperidine ether tropomyosine
MX2016009621A (es) * 2014-01-24 2016-11-17 Abbvie Inc Derivados de fur0-3-carboxamida y metodos de uso.
ES2874533T3 (es) * 2014-02-05 2021-11-05 VM Oncology LLC Composiciones de compuestos y usos de los mismos
CN106232567B (zh) 2014-03-07 2021-11-02 里科瑞尔姆Ip控股有限责任公司 螺桨烷衍生物及合成
WO2015143654A1 (fr) * 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. Inhibiteurs de la kinase trka, compositions et méthodes associées
EP3140298A1 (fr) * 2014-05-07 2017-03-15 Pfizer Inc. Inhibiteurs de kinases apparentées à la tropomyosine
CN103992319B (zh) * 2014-05-27 2015-09-16 天津市斯芬克司药物研发有限公司 一种吡啶羧酸类化合物的制备方法
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016009296A1 (fr) 2014-07-16 2016-01-21 Pfizer Inc. Inhibiteurs de kinase liés à la n-acylpipéridine éther tropomyosine
WO2016020784A1 (fr) 2014-08-05 2016-02-11 Pfizer Inc. Inhibiteurs de kinases apparentées à la n-acylpyrrolidine éther tropomyosine
JP6833677B2 (ja) * 2014-09-17 2021-02-24 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー 二環式化合物
TWI780438B (zh) 2014-12-18 2022-10-11 美商健臻公司 原肌球蛋白相關激酶（ｔｒｋ）抑制劑之醫藥調配物
JP6675324B2 (ja) 2014-12-24 2020-04-01 武田薬品工業株式会社 複素環化合物
CN105837574B (zh) * 2015-02-02 2018-03-02 四川大学 N‑(3‑哌啶基)‑芳香胺衍生物及其制备方法和用途
EP3288556A4 (fr) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Compositions à désintégration par voie orale
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
WO2017027883A1 (fr) 2015-08-13 2017-02-16 San Diego State University Research Foundation Atropisomérisme pour une sélectivité accrue des inhibiteurs de kinase
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
AU2016322813B2 (en) 2015-09-14 2021-04-01 Pfizer Inc. Novel imidazo (4,5-c) quinoline and imidazo (4,5-c)(1,5) naphthyridine derivatives as LRRK2 inhibitors
WO2017059251A1 (fr) 2015-10-02 2017-04-06 Incyte Corporation Composés hétérocycliques utiles en tant qu'inhibiteurs de la kinase pim
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
EP3475280B1 (fr) * 2016-06-23 2020-04-08 H. Hoffnabb-La Roche Ag Nouvelles dérivés de [1,2,3]triazolo[4,5-d]pyrimidine
CN107011347B (zh) * 2017-04-18 2019-01-18 华东师范大学 一种4-氯-7H-吡咯并[2,3-d]嘧啶的合成方法
MX2019013557A (es) 2017-05-15 2022-01-27 Recurium Ip Holdings Llc Compuestos biciclo[1.1.1]pentilo sustituidos y uso de los mismos para el tratamiento del dolor y fiebre.
WO2018237134A1 (fr) 2017-06-23 2018-12-27 San Diego State University Research Foundation Atropisomérisme pour une sélectivité améliorée des inhibiteurs de kinase
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
EP3774800A1 (fr) * 2018-03-28 2021-02-17 Takeda Pharmaceutical Company Limited Composé hétérocyclique et son utilisation
CN109053575A (zh) * 2018-08-24 2018-12-21 遵义医学院 3-环丙基-1-甲基-1h-吡唑-4-甲醛的制备工艺
WO2020084389A1 (fr) * 2018-10-23 2020-04-30 Lupin Limited Intermédiaire de ribociclib et son procédé de préparation
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
JP2021050161A (ja) 2019-09-25 2021-04-01 武田薬品工業株式会社 複素環化合物及びその用途
EP4054579A1 (fr) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Méthodes pour le traitement de cancers qui ont acquis une résistance aux inhibiteurs de kinase
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
AR122141A1 (es) 2020-05-28 2022-08-17 Lilly Co Eli Inhibidor de trka
WO2022268080A1 (fr) * 2021-06-21 2022-12-29 河南迈英诺医药科技有限公司 Composé inhibiteur de la kinase trk et son utilisation

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
TW438796B (en) 1996-05-15 2001-06-07 Hoffmann La Roche 2,4-diaminopyrimidine derivatives, the manufacture process thereof, and the antibiotically-active pharmaceutical composition containing the same
WO2000035298A1 (fr) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing-gum contenant des agents medicamenteux actifs
ATE242245T1 (de) * 1997-03-19 2003-06-15 Basf Ag Pyrrolo(2,3-d)pyrimidine und ihre verwendung als tyrosinkinase-inhibitoren
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
WO2001072751A1 (fr) * 2000-03-29 2001-10-04 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines utilisees comme inhibiteurs de tyrosine kinases
JP2003321472A (ja) 2002-02-26 2003-11-11 Takeda Chem Ind Ltd Ｇｒｋ阻害剤
GB0218168D0 (en) * 2002-08-06 2002-09-11 Astrazeneca Ab Compounds
UA80171C2 (en) 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives
EP1706384A1 (fr) 2004-01-07 2006-10-04 AstraZeneca AB Agents therapeutiques i
US7417063B2 (en) 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
BRPI0511512A (pt) * 2004-05-27 2007-12-26 Pfizer Prod Inc derivados pirrolpirimidina úteis no tratamento do cáncer
WO2007013896A2 (fr) * 2005-05-17 2007-02-01 Plexxikon, Inc. Composes modulant l'activite de c-kit et c-fms et utilisations
US7939556B2 (en) 2005-10-14 2011-05-10 Neurosearch A/S Imidazole derivatives and their use for modulating the GABAA receptor complex
GB0526044D0 (en) 2005-12-21 2006-02-01 Syngenta Ltd Novel herbicides
RU2323058C1 (ru) 2006-07-12 2008-04-27 ООО Научно-внедренческий центр "Машины и оборудование для энергетики" Способ формирования наружной резьбы на концевом участке трубной заготовки
GEP20125425B (en) 2006-10-18 2012-03-26 Pfizer Prod Inc Biaryl ether urea compounds
AU2007336811A1 (en) 2006-12-21 2008-07-03 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
ATE461177T1 (de) 2007-03-23 2010-04-15 Icagen Inc Ionenkanal-hemmer
CN101675040A (zh) 2007-05-03 2010-03-17 辉瑞有限公司 作为钠通道调节剂的2-吡啶甲酰胺衍生物
WO2009012242A2 (fr) 2007-07-13 2009-01-22 Icagen, Inc. Inhibiteurs des canaux sodiques
WO2009012283A1 (fr) 2007-07-17 2009-01-22 Plexxikon Inc. Composés et procédés pour la modulation des kinases et leurs indications
PE20091846A1 (es) 2008-05-19 2009-12-16 Plexxikon Inc DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS
US8158636B2 (en) 2008-05-19 2012-04-17 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
JP5767965B2 (ja) 2008-06-10 2015-08-26 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼを調節する５ｈ−ピロロ［２，３−ｂ］ピラジン誘導体、およびその適応症
WO2009152087A1 (fr) 2008-06-10 2009-12-17 Plexxikon, Inc. Composés hétéroaryles bicycliques et procédés destinés à la modulation de kinases, et des indications pour celle-ci
JP5053459B2 (ja) 2009-01-12 2012-10-17 アイカジェン， インコーポレイテッド スルホンアミド誘導体
KR101483215B1 (ko) * 2010-01-29 2015-01-16 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체
TWI619713B (zh) 2010-04-21 2018-04-01 普雷辛肯公司 用於激酶調節的化合物和方法及其適應症

Also Published As

Publication number Publication date
EA201391239A1 (ru) 2014-03-31
CA2832291A1 (fr) 2012-10-11
EP2694509A1 (fr) 2014-02-12
CA2832291C (fr) 2015-12-01
TW201302757A (zh) 2013-01-16
CU20130129A7 (es) 2014-01-29
IL228590A0 (en) 2013-12-31
AU2012238369A1 (en) 2013-10-03
ES2581848T3 (es) 2016-09-07
JP5595616B2 (ja) 2014-09-24
AR085852A1 (es) 2013-10-30
CR20130470A (es) 2013-10-16
EP2694509B1 (fr) 2016-05-18
UY34004A (es) 2012-11-30
UA108926C2 (ru) 2015-06-25
MX2013011612A (es) 2013-10-17
NZ615557A (en) 2014-08-29
WO2012137089A1 (fr) 2012-10-11
US20120258950A1 (en) 2012-10-11
PE20141050A1 (es) 2014-08-30
TWI443101B (zh) 2014-07-01
NI201300103A (es) 2014-02-12
GEP20156417B (en) 2015-12-25
CL2013002821A1 (es) 2014-02-21
MA35024B1 (fr) 2014-04-03
US8846698B2 (en) 2014-09-30
SG193513A1 (en) 2013-10-30
AP2013007159A0 (en) 2013-10-31
ECSP13013009A (es) 2013-12-31
CO6801740A2 (es) 2013-11-29
JP2014510131A (ja) 2014-04-24
US20140364415A1 (en) 2014-12-11
GT201300236A (es) 2015-08-04
KR20130133905A (ko) 2013-12-09
BR112013025792A2 (pt) 2018-04-24
CN103534257A (zh) 2014-01-22
DOP2013000221A (es) 2014-03-16

Similar Documents

Publication Publication Date Title
TN2013000394A1 (fr) Derives de pyrrolo [2,3-d] pyrimidine servant d'inhibiteurs de kinases apparentees a la tropomyosine
EA201390199A1 (ru) 2-замещенные-8-алкил-7-оксо-7,8-дигидропиридо[2,3-d]пиримидин-6-карбонитрилы и их применение
NZ702571A (en) 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
GEP201706774B (en) Heterocyclyl compounds
NZ626394A (en) Substituted annulated pyrimidines and triazines, and use thereof
MD4735C1 (ro) Derivaţi ai pirolo[2,3-d]pirimidinei ca inhibitori de Kinaze Janus-asociate (JAK)
EA201100580A1 (ru) Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы
CO6831982A2 (es) Pirazolo[4,3-d]pirimidinas útiles como inhibidores de cinasas
GEP201606507B (en) Fused heterocyclic compounds as phosphodiesterases (pdes) inhibitors
RS54339B1 (en) NEW ANTIMALARIAN AGENTS
EA201490912A1 (ru) Производные [1,2,3]триазоло[4,5-d]пиримидина в качестве агонистов каннабиноидного рецептора 2
MA38050B1 (fr) Inhibiteurs de gdf-8
EA201490971A1 (ru) Производные урацила в качестве ингибиторов axl и c-met киназы
MD20140023A2 (ro) Derivaţi de pirolpirimidină şi purină
PH12015500360A1 (en) Pyrazolopyrimidine compound
EA201590224A1 (ru) Имидазотриазинкарбонитрилы, используемые в качестве ингибиторов киназы
NZ703714A (en) 2-aminopyrazine derivatives as csf-1 r kinase inhibitors
EA201290147A1 (ru) Пирроло[2,3-d]пиримидиновые соединения
EA201001017A1 (ru) 3h-[1,2,3]триазоло[4,5-d]пиримидиновые соединения, их применение в качестве ингибиторов киназы mtor и киназы pi3 и их синтезы
TN2009000329A1 (fr) DERIVES DE 2-AMINO-5,7-DIHYDRO-6H-PYRROLO[3,4-d]-PYRIMIDINE SERVANT D'INHBITEURS DE HSP-90 POUR LE TRAITEMENT DU CANCER
JP2016540803A5 (fr)
WO2014053968A8 (fr) Inhibiteurs de kinase associée à la tropomyosine pyrrolo[3,2-c]pyridine
EA200800920A1 (ru) Производные пиразоло[4,3-d]пиримидин-5-ила, применяемые в качестве ингибиторов фосфодиэстеразы 5 (pde5)
WO2013190123A8 (fr) Dérivés de pyrimidinone en tant qu'agents anti-malaria
RS54458B1 (en) TIENO [2,3-D] PYRIMIDINE DERIVATIVES AND THEIR APPLICATIONS IN THE TREATMENT OF ARITHMIA